



PATENT APPLICATION  
File No: 99-16C1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster,  
Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson,  
Stacey R. Dillon, Angela K. Hammond  
Serial No. : 10/659,684  
Group Art Unit : 1644  
Examiner : Seharaseyon, J.  
Filed : September 10, 2003  
For : CYTOKINE ZALPHA11 LIGAND  
Date Submitted : July 12, 2006

**AMENDMENT FEE TRANSMITTAL**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

**CLAIMS AS AMENDED**

<u>Claim Type</u>	<u>Total Claims After Amendment</u>	<u>Highest No. Covered by Previous Payments</u>	<u>Extra</u>	<u>Extra Rate</u>	<u>Fees Paid</u>
Total	<u>48</u>	-47	<u>1</u> x	<input checked="" type="checkbox"/> \$25 <input type="checkbox"/> \$50	\$25.00
Independent	<u>25</u>	-25	<u>0</u> x	<input type="checkbox"/> \$100 <input type="checkbox"/> \$200	\$

Total: \$25.00

Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Deborah A. Sawislak  
Registration No. 37,438



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C.  
Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston,  
Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond  
Serial No. : 10/659,684  
Filed : September 10, 2003  
For : CYTOKINE ZALPHA11 LIGAND  
Confirmation No. : 6041

Examiner : Not Assigned  
Art Unit : 1647  
Docket No. : 99-16C1  
Date : July 12, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT UNDER 37 CFR §1.115(a)(2)**

Sir/Madam:

Applicants respectfully request amendment under 37 CFR §1.115(a)(2) of the above-identified patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** begin on page 3 of this paper.

**Remarks** begin on page 9 of this paper.

07/17/2006 WABDELRL1 00000003 10659684

01 FC:2202

25.00 DA